Study with secukinumab in palmoplantar psoriasis
Research type
Research Study
Full title
A randomised, doubleblind, placebocontrolled, multicentre study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300mg s.c. and to assess safety, tolerability and longterm efficacy up to 132 weeks in subjects with moderate to severe palmoplantar psoriasis.
IRAS ID
126074
Contact name
Catherine Hatchard
Contact email
Sponsor organisation
Novartis Pharmaceuticals
Eudract number
2012-005412-25
ISRCTN Number
n/a
Research summary
Psoriasis is a long lasting disease that appears on the skin. It results in patches of thick, red, raised skin covered with silvery white buildup of dead skin cells called scales. These patches, which are referred to as plaques, may itch or feel
sore. They can occur on any part of the body, including the palms and soles. The cause of psoriasis is not fully understood. It is believed that psoriasis occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells.
In this study we are using a drug called secukinumab, this is a new class of protein based drug ("biologics") which target and neutralise specific chemical messages involved in the disordered immune processes of psoriasis.
In this study suitable patients with palmoplantar psoriasis will receive secukinumab or placebo for approximately 18 months, during which time their palmoplantar psoriasis and safety will be regularly assessed. For the group allocated placebo, after 4 months if they are showing no signs of improvement they will also be allocated secukinumab. The study is looking to recruit 201 patients globally with 7 patients to be recruited from the UK.REC name
London - Surrey Borders Research Ethics Committee
REC reference
13/LO/0665
Date of REC Opinion
27 Jun 2013
REC opinion
Further Information Favourable Opinion